Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow GALECTIN THERAPEUTICS INC

Get SEC filing alerts via email and in your feed for GALECTIN THERAPEUTICS INC

GALT

GALECTIN THERAPEUTICS INC

About GALECTIN THERAPEUTICS INC

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies targeting galectin proteins, especially galectin-3, to treat fibrotic diseases, cancer, and inflammatory conditions. Its lead candidate, belapectin, aims to reverse liver fibrosis and prevent complications in NASH cirrhosis. The company leverages proprietary carbohydrate-based compounds, conducts clinical trials, and seeks strategic partnerships to advance its innovative, patent-protected drug development pipeline.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from GALECTIN THERAPEUTICS INC

1
1
GALECTIN THERAPEUTICS INC Galectin Therapeutics Reports $5M Net Loss in Q1 2026, Focuses on Belapectin Development

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
GALECTIN THERAPEUTICS INC Galectin Therapeutics Reports $30.8 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
GALECTIN THERAPEUTICS INC Galectin Therapeutics Reports $8.2 Million Net Loss in Q3 2025, Decreased R&D Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
GALECTIN THERAPEUTICS INC Galectin Therapeutics Reports Reduced Net Loss and Advances Clinical Trials in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
GALECTIN THERAPEUTICS INC Galectin Therapeutics Reports $9.6 Million Net Loss in Q1 2025, Decreased Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
GALECTIN THERAPEUTICS INC Galectin Therapeutics Reports $47.2 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
GALECTIN THERAPEUTICS INC Galectin Therapeutics Reports Third Quarter Loss, Cash and Cash Equivalents Increase

Via official filing (AI summary) | over 1 year ago | 0 comments